Infectious Disease Diagnostic Market

Infectious Disease Diagnostic Market Outlook (2024 to 2034)

The global infectious disease diagnostic market size is valued at US$ 1,503.8 million in 2024, and it is estimated to expand at a 7.1% CAGR, reaching a valuation of US$ 2,978.7 million by 2034.

Molecular diagnostics, quick testing, automation, and other advancements in diagnostic technology have greatly increased the precision, speed, and effectiveness of diagnosing infectious diseases. Through the provision of improved instruments for the early identification and surveillance of infectious illnesses, these advances support the market's expansion. Infectious diseases, especially new and re-emerging infections, are growing increasingly prevalent globally. As a result, there is a greater demand for precision diagnostic technologies that enable early identification and intervention.

Key Trends Boosting Infectious Disease Diagnostic Market Growth

“Rising Adoption of Point-of-Care Technologies (POCT)”

The growing use of Point-of-Care Testing (POCT) indicates a deliberate move away from centralized diagnostic solutions and toward decentralized ones, which enable companies to meet customer demands for quick and convenient diagnostics. This trend gives businesses that offer POCT solutions a competitive edge by facilitating speedier decision-making and patient management. It also corresponds with market expectations for effective healthcare delivery in resource-constrained environments.

“Growing Advancements in Next-generation Sequencing (NGS)”

Businesses that specialize in the diagnosis of infectious diseases are making use of Next-Generation Sequencing (NGS) technology developments. Businesses are offering innovative solutions to meet the increasing need for genetic diversity studies in infectious agents and comprehensive surveillance applications by integrating quicker and more affordable sequencing capabilities.

“Rising Focus on Antimicrobial Resistance (AMR)”

It is strategically vital for firms to develop diagnostic tests that can promptly identify drug-resistant types of bacteria, given growing concerns over antimicrobial resistance (AMR). Businesses that match their products to this niche must proactively position themselves to tackle a pressing issue in global health by delivering solutions that support efficient administration and treatment.

“Growing Demand for Rapid Diagnostic Tests (RDTs)”

Rapid Diagnostic Tests (RDTs) are in high demand, creating significant possibilities for enterprises to profit from the need for swift and on-the-spot reports in point-of-care settings. Businesses can develop a strong competitive advantage and fulfill the changing needs of healthcare professionals and end-users by delivering solutions that guarantee fast decision-making and effective patient management.

Report Attributes	Details
Estimated Market Value (2024E)	US$ 1,503.8 million
Forecasted Market Value (2034F)	US$ 2,987.7 million
Global Market Growth Rate (2024 to 2034)	7.1% CAGR
STDs Disease Indication Segment Growth Rate (2024 to 2034)	8.3%
Cell Culture Technique Segment Growth Rate (2024 to 2034)	8.3%
North America Market Share (2024)	20.9%
East Asia Market Share (2024)	17.7%
Key Companies Profiled	Roche Diagnostics Abbott Laboratories Siemens Healthineers Thermo Fisher Scientific BioMérieux SA Becton, Dickinson and Company Cepheid (a Danaher Corporation company) Hologic, Inc. QIAGEN N.V. Bio-Rad Laboratories, Inc. Luminex Corporation Ortho Clinical Diagnostics DiaSorin S.p.A. Meridian Bioscience, Inc. GenMark Diagnostics, Inc.

Which Factors Are Boosting the Demand for Infectious Disease Diagnostics?

“Emergence of Zoonotic Diseases and Environmental Changes”

Urbanization and climate change are two environmental changes that lead to the rise of zoonotic illnesses. Businesses that provide zoonotic diagnostic services can differentiate themselves by comprehending the relationship between disease transmission dynamics and environmental changes. This entails creating diagnostic instruments that target zoonotic pathogens specifically, meeting a particular market demand, and positioning the business as a pioneer in the rapidly changing field of infectious disease diagnostics.

“Rising Emphasis on Preventive Healthcare Measures”

The focus on preventative healthcare highlights the need for transmissible disease diagnostics as essential to regular physical examinations. Companies that correlate their offerings with this trend portray themselves as indispensable for proactive health management. This includes marketing initiatives highlighting the importance of diagnostics in early detection and prevention, generating a favorable view of the company's capabilities among healthcare providers and end-users. These firms encourage market development by promoting diagnostic products as key components of wellness plans.

“Global Focus on Prioritizing Health Security”

The growing risk of epidemics and bioterrorism has prompted governments and international organizations to place a high priority on global health security. In order to improve epidemic preparedness and response capacities, significant investments are required in cutting-edge infectious disease diagnostics. Businesses that strategically link their offerings with these global health security initiatives stand to gain from increased demand for state-of-the-art diagnostic solutions, giving them a competitive edge in a market where public health concerns drive demand.

Which Factors Restrain this Market’s Growth Prospects?

“Disparities in Global Healthcare Infrastructure”

Differences hamper the general embrace of modern technology in the diagnostic and medical infrastructure across developed and developing regions. Underprivileged populations are susceptible to delayed or insufficient identification and treatment of infectious illnesses as a result of limited resources in some regions of the world, thereby impeding the broad use of advanced diagnostic methods.

“Growing Antibiotic Resistance in Patients”

The growing issue of antibiotic resistance makes diagnosing infectious diseases more difficult. Finding appropriate medicines is harder when infections develop resistance to standard therapies. When it comes to helping medical practitioners prescribe focused and successful drugs, diagnostic tools need to be updated regularly. To stay up with the ever-changing risks posed by microorganisms, diagnostics must constantly innovate due to the growing intricacy of antibiotic resistance patterns.

Country-wise Insights

The United States infectious disease diagnostic market is anticipated to witness significant expansion, leading at a 6.7% CAGR through 2034 in North America. According to estimates, China is anticipated to lead the East Asia infectious disease diagnostic market with an 8.7% CAGR until 2034.

Why is the Demand Expanding in the United States?

“Growing Emphasis on Preventive Care Boosts Demand in the United States”

Country	Value CAGR (2024 to 2034)
United States	6.7%

The demand for infectious disease diagnostics in the United States is poised to rise at a 6.7% CAGR through 2034. The market growth in the United States is influenced by the shift in healthcare policies that emphasize preventative treatment. Deploying value-based care models and reimbursement processes incentivizing early identification and intervention provides a conducive environment. Diagnostic firms that carefully match their products with preventive healthcare goals stand to gain from the increasing emphasis on cost-effective and proactive healthcare procedures. This change accommodates changing patient preferences and positions enterprises as contributors to larger healthcare goals, strengthening their market presence in the volatile American healthcare sector.

Why is Demand Surging in China at a Higher CAGR?

“Rising Health Consciousness Trends Nurture Growth in China”

Country	Value CAGR (2024 to 2034)
China	8.7%

The infectious disease diagnostics market in China is estimated to have an 8.7% CAGR through 2034. The rising middle-class population in China and a growing health-consciousness trend are driving market expansion for infectious disease diagnostics. As people grow more health-conscious, there is a greater need for preventative healthcare interventions, such as early illness diagnosis. Diagnostic firms that promote their goods as essential to health-conscious lifestyles benefit from this trend. This entails strategic marketing initiatives that emphasize the relevance of diagnostics in preventative healthcare, thereby reflecting the ideals and ambitions of China's increasing middle-class populace.

Category-wise Insights

Why are STDs the Leading Disease Indication Segment?

“Technological Advancements Boost Demand for STD Diagnostics”

Attribute	STDs (Disease Indication)
Segment Value (2024E)	US$ 532.5 million
Growth Rate (2024 to 2034)	8.3% CAGR
Projected Value (2034F)	US$ 1,176.7 million

STD diagnostics are in high demand due in part to ongoing developments in diagnostic technology. Increased test sensitivity and specificity, quick diagnostic techniques, and creating point-of-care testing choices improve the entire diagnostic experience. The availability of effective and user-friendly diagnostic equipment motivates more people to be tested.

Several STDs, such as gonorrhea and chlamydia, can exhibit no symptoms at all, which makes infections go undiagnosed and untreated. Given that people aren't always aware of their infection status, the high incidence of asymptomatic infections highlights the significance of routine testing. The growing need for tests that can identify infections even without symptoms is partly due to diagnostic businesses' response to this requirement.

Why is Cell Culture the Leading Technique in this Market?

“Critical Role in Developing Novel Therapies Surges Demand for Cell Culture Technique”

Attribute	Cell Culture (Technique)
Segment Value (2024E)	US$ 588.7 million
Growth Rate (2024 to 2034)	8.3% CAGR
Projected Value (2034F)	US$ 1,304.6 million

Cell culture techniques play an important role in the industry in developing innovative treatment strategies such as cell-based therapeutics and personalized healthcare approaches. Infectious disease diagnostics involves researching novel treatments such as viral vector-based therapeutics and cell-based immunotherapies. Cell culture is in high demand due to its critical role in the advancement of these cutting-edge treatment techniques.

New developments in three-dimensional (3D) cell culture models improve the precision and applicability of studies on infectious diseases. By more closely resembling the intricate milieu of tissues and organs, these models enable researchers to examine infections in a more physiologically relevant setting. The rapid increase in the demand for 3D cell culture indicates the industry's dedication to developing research methods for an improved understanding of infectious illnesses.

Competitive Landscape

Key players in the infectious disease diagnostic market include Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, Thermo Fisher Scientific, BioMérieux SA, Becton, Dickinson and Company, Cepheid (a Danaher Corporation company), Hologic, Inc., QIAGEN N.V., Bio-Rad Laboratories, Inc., Luminex Corporation, Ortho Clinical Diagnostics, DiaSorin S.p.A., Meridian Bioscience, Inc., and GenMark Diagnostics, Inc.

The infectious disease diagnostic market is highly competitive, with significant rivals fighting for market share and innovation supremacy. Market leaders concentrate on smart mergers and acquisitions to increase their global reach, add specialized technology, and diversify their product offerings. They hope to improve their competitive standing and increase their market reach by taking these calculated risks.

Recent Developments

• In November 2023, Apollo Cancer Centres (ACCs) launched ‘India's Fastest & Precise Breast Cancer Diagnosis Program.’ This project seeks to deliver rapid and accurate breast cancer diagnostics, emphasizing the importance of early diagnosis in determining the best therapy for patients and improving their quality of life.
• In October 2023, Precede Biosciences entered the market with cell-free genomic diagnostics for drug development and precision medicine.

Infectious Disease Diagnostic Market Segmentation

• By Disease Indication:

  • CNS Infection
  • Diarrhoeal Disease
  • Respiratory Infections
  • Blood Infections
  • STDs

• By Technique:

  • ELISA
  • Polymerase Chain Reaction
  • Immunoassays
  • Cell Cultures
  • Others

• By End User:

  • Hospitals
  • Diagnostic Centers
  • Clinics
  • Government Organizations

• By Region:

  • North America
  • Europe
  • Latin America
  • East Asia
  • South Asia & Oceania
  • The Middle East & Africa